¼¼°èÀÇ Ç츣Æä½º ¸¶Ä¿ °Ë»ç ½ÃÀå
Herpes Marker Testing
»óǰÄÚµå : 1565003
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 159 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,056,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,169,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Ç츣Æä½º ¸¶Ä¿ °Ë»ç ¼¼°è ½ÃÀåÀº 2030³â±îÁö 6¾ï 5,410¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î Àü¸Á

2023³â 4¾ï 6,810¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â Ç츣Æä½º ¸¶Ä¿ °Ë»ç ¼¼°è ½ÃÀåÀº 2030³â±îÁö 6¾ï 5,410¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2023-2030³â µ¿¾È 4.9%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ Áø´Ü ¼¾ÅÍ ÃÖÁ¾ ¿ëµµ ºÎ¹®Àº CAGR 5.7%¸¦ ±â·ÏÇÏ¿© ºÐ¼® ±â°£ Á¾·á ½ÃÁ¡¿¡ 2¾ï 7,990¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. º´¿ø ÃÖÁ¾ ¿ëµµ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 4.6%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 1¾ï 2,410¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 7.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î Àü¸Á

¹Ì±¹ÀÇ Ç츣Æä½º ¸¶Ä¿ °Ë»ç ½ÃÀåÀº 2023³â 1¾ï 2,410¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2023-2030³â ºÐ¼® ±â°£ µ¿¾È 7.5%ÀÇ CAGR·Î 2030³â±îÁö 1¾ï 4,570¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´Ù¸¥ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ª ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ µ¿¾È °¢°¢ 2.4%¿Í 4.6%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ 2.8%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°è Ç츣Æä½º ¸¶Ä¿ °Ë»ç ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ ¿ä¾à

Ç츣Æä½º ¸¶Ä¿ °Ë»ç°¡ ¹ÙÀÌ·¯½º °¨¿°À» È¿°úÀûÀ¸·Î °ü¸®ÇÒ ¼ö ÀÖ´Â ¿­¼è°¡ µÉ ¼ö ÀÖÀ»±î?

Ç츣Æä½º ¸¶Ä¿ °Ë»ç´Â ´Ü¼øÆ÷Áø¹ÙÀÌ·¯½º(HSV) °¨¿°À» Áø´ÜÇÏ°í °ü¸®ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϴµ¥, ¿Ö ÀÌ °Ë»ç°¡ ÇʼöÀûÀΰ¡? Ç츣Æä½º ¸¶Ä¿ °Ë»ç´Â ü³» Ç×ü ¶Ç´Â ¹ÙÀÌ·¯½º DNAÀÇ Á¸À縦 °¨ÁöÇÏ´Â µ¥ »ç¿ëµÇ¸ç, ÀÓ»óÀǰ¡ °¡Àå ÈçÇÑ µÎ °¡Áö ¹ÙÀÌ·¯½º ±ÕÁÖ ÀÎ HSV-1 ¶Ç´Â HSV-2¿¡ °¨¿°µÇ¾ú´ÂÁö ¿©ºÎ¸¦ ½Äº°ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.´Â »ý½Ä±â Æ÷Áø°ú °ü·ÃÀÌ ÀÖÁö¸¸, µÎ À¯Çü ¸ðµÎ µÎ ºÎÀ§ ¸ðµÎ¿¡ °¨¿°µÉ ¼ö ÀÖ½À´Ï´Ù. Ç츣Æä½º °¨¿°Àº ³Î¸® ÆÛÁ® ÀÖÀ¸¸ç, Àü ¼¼°èÀûÀ¸·Î ¼ö¹é¸¸ ¸íÀÇ »ç¶÷µéÀÌ µÎ °¡Áö À¯ÇüÀÇ ¹ÙÀÌ·¯½º¿¡ °¨¿°µÈ ä·Î »ì¾Æ°¡°í ÀÖ½À´Ï´Ù. À̵é Áß »ó´ç¼ö´Â ¹«Áõ»óÀÎ °æ¿ì°¡ ¸¹±â ¶§¹®¿¡ ÀÚ½ÅÀÌ º¸±ÕÀÚ¶ó´Â »ç½ÇÀ» ¾ËÁö ¸øÇÕ´Ï´Ù.

Ç츣Æä½º ¸¶Ä¿ °Ë»ç´Â ƯÈ÷ ¹«Áõ»óÀÚ³ª °æÁõ ȯÀÚ°¡ Àڽŵµ ¸ð¸£°Ô ´Ù¸¥ »ç¶÷¿¡°Ô ¹ÙÀÌ·¯½º¸¦ Àü¿°½Ãų ¼ö Àֱ⠶§¹®¿¡ ¹ÙÀÌ·¯½º Áø´Ü¿¡ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. Ç츣Æä½º °Ë»ç´Â ¸é¿ª ü°è°¡ °¨¿°¿¡ ¹ÝÀÀÇÏ¿© »ý¼ºÇϴ ƯÁ¤ Ç×ü(IgG ¶Ç´Â IgM)¸¦ È®ÀÎÇϰųª ÁßÇÕÈ¿¼Ò ¿¬¼â ¹ÝÀÀ(PCR) °Ë»ç¸¦ ÅëÇØ ¹ÙÀÌ·¯½º DNA¸¦ °ËÃâÇÕ´Ï´Ù. ÀÌ·¯ÇÑ °Ë»ç´Â ´©±º°¡°¡ ¹ÙÀÌ·¯½º¿¡ ³ëÃâµÇ¾ú´ÂÁö ¿©ºÎ¸¦ È®ÀÎÇÏ´Â µ¥ µµ¿òÀÌ µÇ¸ç, Á¾Á¾ °¨¿°ÀÌ ÃÖ±Ù ¶Ç´Â Àå±âÀûÀÎÁö ¿©ºÎ¸¦ ³ªÅ¸³¾ ¼ö ÀÖ½À´Ï´Ù. Ç츣Æä½º ¸¶Ä¿ °Ë»ç¸¦ ÅëÇÑ Á¤È®ÇÑ Áø´ÜÀº ¹ßº´À» °ü¸®Çϰí, °¨¿° À§ÇèÀ» ÁÙÀ̰í, °³ÀÎÀÇ Áõ»óÀ» °ü¸®Çϰí ÇÕº´ÁõÀ» ¿¹¹æÇϱâ À§ÇÑ Ä¡·á¹ýÀ» ¾È³»ÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù.

±â¼úÀº ¾î¶»°Ô Ç츣Æä½º ¸¶Ä¿ °Ë»ç¸¦ ¹ßÀü½ÃÄ״°¡?

±â¼úÀÇ ¹ßÀüÀº Ç츣Æä½º ¸¶Ä¿ °Ë»ç¸¦ ´õ Á¤È®ÇÏ°í ºü¸£°í ½±°Ô Á¢±Ù ÇÒ ¼ö ÀÖµµ·Ï Å©°Ô °³¼±Çß½À´Ï´Ù. ÀÌ ºÐ¾ßÀÇ °¡Àå Áß¿äÇÑ Çõ½Å Áß Çϳª´Â ¹ÙÀÌ·¯½º DNA¸¦ Á÷Á¢ °ËÃâÇÒ ¼ö ÀÖ´Â ÁßÇÕÈ¿¼Ò ¿¬¼â ¹ÝÀÀ(PCR) °Ë»çÀÇ °³¹ß·Î, PCR °Ë»ç´Â ¸Å¿ì ¹Î°¨ÇÏ¿© Ç÷¾×, Ÿ¾×, º´º¯ ¸éºÀ µî ´Ù¾çÇÑ ½Ã·á À¯Çü¿¡¼­ ¼Ò·®ÀÇ ¹ÙÀÌ·¯½ºµµ °ËÃâÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ¹æ¹ýÀº ½Å¼ÓÇϰí Á¤È®ÇÑ °á°ú¸¦ Á¦°øÇϸç, Á¾Á¾ ¸î ½Ã°£ ³»¿¡ Ȱ¼º Ç츣Æä½º °¨¿°À» °¨ÁöÇÒ ¼ö ÀÖ´Â °¡Àå ½Å·ÚÇÒ ¼ö ÀÖ´Â Áø´Ü µµ±¸ Áß ÇϳªÀ̸ç, PCR °Ë»ç´Â HSV °¨¿° Áø´ÜÀÇ Ç¥ÁØÀÌ µÇ¾ú½À´Ï´Ù. ÇÊ¿äÇÑ °æ¿ì¿¡ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.

HSV¿¡ ´ëÇÑ Ç×üÀÇ Á¸À縦 È®ÀÎÇÏ´Â Ç÷ûÇÐÀû °Ë»çµµ ¹ßÀüÇϰí ÀÖ½À´Ï´Ù. ±âÁ¸ÀÇ Ç÷¾× °Ë»ç·Î´Â HSV-1°ú HSV-2 °¨¿°À» ±¸º°ÇÏ´Â µ¥ ¾î·Á¿òÀÌ ÀÖ¾ú½À´Ï´Ù. ±×·¯³ª ÃֽŠÇ÷ûÇÐÀû °Ë»ç´Â HSV-1°ú HSV-2¿¡ ƯÀÌÀûÀÎ Ç×ü¸¦ °ËÃâÇÒ ¼ö ÀÖ°Ô µÇ¾î ÀÓ»óÀǰ¡ HSV-1°ú HSV-2¸¦ ±¸º°ÇÒ ¼ö ÀÖ°Ô µÇ¾úÀ¸¸ç, HSV-1°ú HSV-2´Â Àü¿° ÆÐÅϰú Àç¹ß·üÀÌ ´Ù¸£±â ¶§¹®¿¡ ÀÌ ±¸º°Àº ¸Å¿ì Áß¿äÇÕ´Ï´Ù. À¯Çüº° IgG Ç×ü °Ë»ç´Â °ú°Å °¨¿° ¿©ºÎ¸¦ ³ªÅ¸³¾ ¼ö ÀÖÀ¸¸ç, IgM °Ë»ç´Â ÃÖ±Ù ¶Ç´Â ÀÏÂ÷ °¨¿°À» ½Äº°ÇÏ´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

¶ÇÇÑ, Ç츣Æä½º ÇöÀå °Ë»ç(POC)°¡ Á¡Á¡ ´õ ¸¹ÀÌ ÀÌ¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½Å¼Ó °Ë»ç´Â ±× ÀÚ¸®¿¡¼­ ¹Ù·Î °á°ú¸¦ ¾òÀ» ¼ö Àֱ⠶§¹®¿¡ ½Å¼ÓÇÑ Áø´ÜÀÌ Áß¿äÇÑ ÀÀ±Þ½ÇÀ̳ª ¼ºº´ Ŭ¸®´Ð¿¡¼­ À¯¿ëÇÏ°Ô »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. »õ·Î¿î ±â¼úÀº HSV¿Í ¿©·¯ ¼ºº´(STI)À» µ¿½Ã¿¡ °ËÃâÇÒ ¼ö ÀÖ´Â ¸ÖƼÇ÷º½º °Ë»çµµ °³¹ßµÇ¾î È¿À²¼ºÀ» ³ôÀ̰í Áߺ¹ °¨¿°À» Áø´ÜÇÏ´Â µ¥ ÇÊ¿äÇÑ °Ë»ç Ƚ¼ö¸¦ ÁÙÀ̰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ç츣Æä½º ¸¶Ä¿ °Ë»çÀÇ ¹ßÀüÀº Áø´Ü Á¤È®µµ¸¦ Çâ»ó½Ãų»Ó¸¸ ¾Æ´Ï¶ó ÇÁ·Î¼¼½º¸¦ °¡¼ÓÈ­ÇÏ¿© Ç츣Æä½º °¨¿°¿¡ ´ëÇÑ Á¶±â °³ÀÔ°ú ´õ ³ªÀº °ü¸®¸¦ °¡´ÉÇϰÔÇÕ´Ï´Ù.

Ç츣Æä½º ¸¶Ä¿ °Ë»ç°¡ °øÁß º¸°Ç ¹× °³ÀÎ °ü¸®¿¡ ÇʼöÀûÀÎ ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

Ç츣Æä½º ¸¶Ä¿ °Ë»ç´Â °øÁß º¸°Ç ¹× °³ÀÎ °ü¸®¿¡ ÇʼöÀûÀÔ´Ï´Ù. Ç츣Æä½º ¸¶Ä¿ °Ë»ç¸¦ ÅëÇØ °³Àΰú ÀÇ·áÁøÀÌ Ç츣Æä½º ¹ÙÀÌ·¯½º °¨¿°À» °¨ÁöÇϰí, ƯÈ÷ Áõ»óÀÌ °æ¹ÌÇϰųª ¹«Áõ»óÀÎ °æ¿ì °¨¿° È®»êÀ» ¾ïÁ¦ÇÒ ¼ö Àֱ⠶§¹®ÀÔ´Ï´Ù. Ç츣Æä½º ¹ÙÀÌ·¯½º´Â Àå±â°£ ü³»¿¡ Àáº¹ÇØ ÀÖ´Ù°¡ ½ºÆ®·¹½º, Áúº´, ¸é¿ª·Â ÀúÇÏ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ óÀ½ ¹ßº´Çϱ⠶§¹®¿¡ ´ëºÎºÐÀÇ Ç츣Æä½º °¨¿°ÀÚ´Â °¨¿° »ç½ÇÀ» ÀÎÁöÇÏÁö ¸øÇÕ´Ï´Ù. ÀûÀýÇÑ °Ë»ç¸¦ ¹ÞÁö ¾ÊÀ¸¸é ÀÌ·± »ç¶÷µéÀº Àڽŵµ ¸ð¸£°Ô ´Ù¸¥ »ç¶÷¿¡°Ô ¹ÙÀÌ·¯½º¸¦ Àü¿°½ÃÄÑ °¨¿°À» È®»ê½Ãų ¼ö ÀÖ½À´Ï´Ù. Ç츣Æä½º ¸¶Ä¿ °Ë»ç´Â º¸±ÕÀÚ¸¦ ½Äº°Çϰí Ç×¹ÙÀÌ·¯½ºÁ¦ »ç¿ë, ¾ÈÀüÇÑ ¼ºÇàÀ§ ½Çõ µî °¨¿° À§ÇèÀ» ÁÙÀ̱â À§ÇÑ ¿¹¹æ Á¶Ä¡¸¦ ÃëÇÏ´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

Ç츣Æä½º ¸¶Ä¿ °Ë»ç´Â ƯÈ÷ ¼º±â³ª ±¸°­ÀÇ ±Ë¾ç, °¡·Á¿òÁõ, ºÒÆí°¨ µî ¿øÀÎÀ» ¾Ë ¼ö ¾ø´Â Áõ»óÀ» °æÇèÇÏ´Â °æ¿ì, °³Àο¡°Ô È®½ÇÇÑ ¾Èµµ°¨À» ÁÙ ¼ö ÀÖ½À´Ï´Ù. È®Áø Áø´ÜÀ» ÅëÇØ ÀÇ·áÁøÀº ¾Æ½ÃŬ·Î¹ö, ¹Ù¶ó½Ã½Ãºñ¸£ ¶Ç´Â ÆÊ½Ã½Ãºñ¸£¿Í °°Àº Ç×¹ÙÀÌ·¯½º ¾à¹°À» Æ÷ÇÔÇÏ¿© ¹ßº´ ºóµµ¿Í ½É°¢¼ºÀ» ÁÙÀ̱â À§ÇÑ ¸ÂÃãÇü °ü¸® °èȹÀ» ¼¼¿ï ¼ö ÀÖ½À´Ï´Ù. ÀÚ½ÅÀÇ HSV »óŸ¦ ¾Æ´Â °ÍÀº ƯÈ÷ ¹«Áõ»ó ¹è¼³¹°¿¡¼­ ¹ÙÀÌ·¯½º°¡ ¿©ÀüÈ÷ °¨¿°µÉ ¼ö ÀÖ´Â µ¿¾È ¼º ÆÄÆ®³Ê¿¡°Ô ¹ÙÀÌ·¯½º¸¦ Àü¿°½ÃŰÁö ¾Êµµ·Ï ¿¹¹æ Á¶Ä¡¸¦ ÃëÇÏ´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

ÀÓ»êºÎÀÇ °æ¿ì Ç츣Æä½º ¸¶Ä¿ °Ë»ç°¡ ƯÈ÷ Áß¿äÇѵ¥, HSV °¨¿°Àº ƯÈ÷ ÀӽŠÁß¿¡ ¹ßº´ÇÏ¸é ¾Æ±â¿¡°Ô À§ÇèÀ» ÃÊ·¡ÇÒ ¼ö ÀÖÀ¸¸ç ½Å»ý¾Æ Ç츣Æä½º·Î À̾îÁú ¼ö Àֱ⠶§¹®ÀÔ´Ï´Ù. Ç츣Æä½º °¨¿°À» Á¶±â¿¡ ¹ß°ßÇϸé ÀÇ»ç´Â ÀӽŠÈı⿡ Ç×¹ÙÀÌ·¯½ºÁ¦¸¦ ó¹æÇϰųª ºÐ¸¸ Áß È°µ¿¼º º´º¯ÀÌ ÀÖ´Â °æ¿ì Á¦¿ÕÀý°³ ºÐ¸¸À» ±ÇÀ¯ÇÏ´Â µî ¿¹¹æ Á¶Ä¡¸¦ ÃëÇØ ½Å»ý¾Æ¿¡°Ô ¹ÙÀÌ·¯½º¸¦ Àü¿°½Ãų À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù.

º¸´Ù Å« ±Ô¸ð¿¡¼­, Ç츣Æä½º ¸¶Ä¿ °Ë»ç´Â HSV °¨¿°ÀÌ °øÁß º¸°Ç¿¡ ¹ÌÄ¡´Â Àüü ¿µÇâÀ» °ü¸®Çϱâ À§ÇØ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. Ç츣Æä½º ¹ÙÀÌ·¯½º´Â Àü ¼¼°èÀûÀ¸·Î °¡Àå ³Î¸® ÆÛÁø ¼ºº´ Áß ÇϳªÀ̸ç, ±¤¹üÀ§ÇÑ °Ë»ç¸¦ ÅëÇØ º¸±ÕÀÚ¸¦ ½Äº°Çϰí Ä¡·áÇÔÀ¸·Î½á Àü¿°·üÀ» ³·Ãâ ¼ö ÀÖ½À´Ï´Ù. Ç츣Æä½º °¨¿°À» Á¶±â¿¡ ¹ß°ßÇϰí È¿°úÀûÀ¸·Î °ü¸®ÇÏ¸é °Ë»ç ¹× Ä¡·á¸¦ ¹Þ´Â °ÍÀ» ¹æÇØÇÏ´Â ¹ÙÀÌ·¯½º °ü·Ã Æí°ßÀ» ÁÙÀÌ´Â µ¥µµ µµ¿òÀÌ µË´Ï´Ù. °Ë»ç¸¦ Á¤»óÈ­Çϰí Áø´Ü¿¡ ½±°Ô Á¢±ÙÇÒ ¼ö ÀÖµµ·ÏÇÔÀ¸·Î½á °øÁߺ¸°Ç ½Ã½ºÅÛÀº HSVÀÇ È®»êÀ» º¸´Ù È¿°úÀûÀ¸·Î °ü¸®Çϰí Ãë¾àÇÑ Áý´ÜÀ» º¸È£ÇÏ¸ç ¹ÙÀÌ·¯½º¿¡ °¨¿°µÈ »ç¶÷µéÀÇ »îÀÇ ÁúÀ» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù.

Ç츣Æä½º ¸¶Ä¿ °Ë»ç ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

Ç츣Æä½º ¸¶Ä¿ °Ë»ç ½ÃÀåÀÇ ¼ºÀåÀº ¼ºº´(STI)¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, °Ë»ç ±â¼úÀÇ ¹ßÀü, ´Ü¼ø Æ÷Áø ¹ÙÀÌ·¯½º °¨¿°ÀÇ Àü ¼¼°è À¯º´·ü Áõ°¡ µî ¸î °¡Áö Áß¿äÇÑ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ÃËÁø¿äÀÎ Áß Çϳª´Â STI¿¡ ´ëÇÑ ÀνÄÀÇ Áõ°¡¿Í Á¤±âÀûÀÎ °ËÁøÀÇ Á߿伺ÀÔ´Ï´Ù. °øÁߺ¸°Ç Ä·ÆäÀΰú ±³À° ÇÁ·Î±×·¥Àº ƯÈ÷ HSV °¨¿°ÀÇ ¹«Áõ»ó¼º¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ´õ ¸¹Àº »ç¶÷µéÀÌ Ç츣Æä½º ¹× ±âŸ STI¿¡ ´ëÇÑ °Ë»ç¸¦ ¹Þµµ·Ï Àå·ÁÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °øÁߺ¸°Ç ÀνÄÀÇ º¯È­´Â Áø·á¼Ò, º´¿ø ¹× °¡Á¤¿ë °Ë»ç ŰƮ¿¡ ´ëÇÑ Ç츣Æä½º ¸¶Ä¿ °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î À̾îÁö°í ÀÖ½À´Ï´Ù.

Áø´Ü °Ë»çÀÇ ±â¼ú ¹ßÀüµµ Ç츣Æä½º ¸¶Ä¿ °Ë»ç ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, PCR ¹× ¸ÖƼÇ÷º½º °Ë»ç¿Í °°ÀÌ º¸´Ù Á¤È®ÇÏ°í ½Å¼ÓÇÏ¸ç ºñ¿ë È¿À²ÀûÀÎ °Ë»çÀÇ °³¹ß·Î Ç츣Æä½º Áø´ÜÀÌ ÀÇ·á ¼­ºñ½º Á¦°øÀÚ¿Í È¯ÀÚ¿¡°Ô ´õ¿í Ä£¼÷ÇØÁ³½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀ» ÅëÇØ ½Å¼ÓÇÑ ´ëÀÀÀÌ °¡´ÉÇØÁ³À¸¸ç, À̴ ƯÈ÷ ±Þ¼º ¹ßº´ °ü¸® ¹× Àü¿° ¿¹¹æ¿¡ ÀÖ¾î ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ½Å¼ÓÇÑ °á°ú¸¦ Á¦°øÇÏ´Â ÇöÀåÁø´Ü(POC, Point-of-Care) °Ë»çÀÇ µµÀÔµµ ½ÃÀå È®´ë¸¦ ÃËÁøÇÏ´Â ¿äÀÎ Áß ÇϳªÀ̸ç, ƯÈ÷ ÀÇ·á ÀÎÇÁ¶ó°¡ Á¦ÇÑÀûÀ̰ųª Ä¡·á ¹æÄ§À» °áÁ¤Çϱâ À§ÇØ Áï°¢ÀûÀÎ °á°ú°¡ ÇÊ¿äÇÑ Áö¿ª¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

Ç츣Æä½º °¨¿°ÀÇ À¯º´·üÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â Áß¿äÇÑ ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)´Â 50¼¼ ¹Ì¸¸ÀÇ 37¾ï ¸í ÀÌ»óÀÌ HSV-1¿¡ °¨¿°µÈ °ÍÀ¸·Î ÃßÁ¤Çϰí ÀÖÀ¸¸ç, 15-49¼¼ÀÇ 4¾ï 9,000¸¸ ¸í ÀÌ»óÀÌ HSV-2¿¡ °¨¿°µÈ °ÍÀ¸·Î ÃßÁ¤Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °¨¿°ÀÌ ¿©ÀüÈ÷ ¸¸¿¬ÇÏ°í ºÒÄ¡º´ÀÎ ¸¸Å­, Ç츣Æä½º °¨¿°À» °ü¸®ÇÏ°í ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ´Â È¿°úÀûÀÎ Áø´Ü µµ±¸¿¡ ´ëÇÑ ¼ö¿ä´Â °è¼Ó Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀӽŠÁß ÇÕº´Áõ ¹× HIV ÀüÆÄ À§Çè Áõ°¡ µî ¹ÌÁø´Ü ¶Ç´Â ¹ÌÄ¡·á Ç츣Æä½º °ü·Ã °Ç°­ À§Çè¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ °Ë»ç¸¦ ¹ÞÀ¸·Á´Â »ç¶÷µéÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

ÀçÅà °Ë»ç ¿É¼ÇÀÇ Áõ°¡µµ ½ÃÀå È®´ë¿¡ ±â¿©ÇÏ´Â Ãß¼¼ÀÔ´Ï´Ù. ¿ø°ÝÀÇ·á¿Í µðÁöÅÐ °Ç°­ Ç÷§ÆûÀÇ ºÎ»óÀ¸·Î ÀçÅà Ç츣Æä½º °Ë»ç ŰƮ°¡ Á¡Á¡ ´õ º¸ÆíÈ­µÇ°í ÀÖÀ¸¸ç, °³ÀÎÀÌ HSV »óŸ¦ ¾Ë ¼ö ÀÖ´Â Æí¸®ÇÏ°í ´«¿¡ Àß ¶çÁö ¾ÊÀ¸¸ç ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¹æ¹ýÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù. ÀÌ Å°Æ®´Â »ç¿ëÀÚ°¡ Áý¿¡¼­ »ùÇÃÀ» äÃëÇÏ¿© ºÐ¼®À» À§ÇØ °Ë»ç ±â°ü¿¡ º¸³¾ ¼ö ÀÖÀ¸¸ç, °á°ú´Â ¾ÈÀüÇÑ ¿Â¶óÀÎ Ç÷§ÆûÀ» ÅëÇØ ºñ¹Ð¸®¿¡ Á¦°øµË´Ï´Ù. ÀÌ·¯ÇÑ ¼­ºñ½º°¡ Á¦°øÇÏ´Â Æí¸®ÇÔ°ú ÇÁ¶óÀ̹ö½Ã´Â ´õ ¸¹Àº »ç¶÷µé, ƯÈ÷ ÀþÀº Ãþ°ú ±â¼ú¿¡ Á¤ÅëÇÑ »ç¶÷µéÀÌ ÀÚ½ÅÀÇ ¼º °Ç°­À» °ü¸®ÇÏ°í °Ë»ç¸¦ ¹Þµµ·Ï Àå·ÁÇϰí ÀÖ½À´Ï´Ù.

¸¶Áö¸·À¸·Î, ¼ºº´ÀÇ È®»êÀ» ÁÙÀ̱â À§ÇÑ ÀÇ·á ÀÌ´Ï¼ÅÆ¼ºê¿Í Á¤ºÎ ÇÁ·Î±×·¥ÀÇ Áõ°¡´Â Ç츣Æä½º ¸¶Ä¿ °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. °¢±¹ Á¤ºÎ¿Í Àü ¼¼°è º¸°Ç ±â°üÀº Ç츣Æä½º ¹× ±âŸ °¨¿°¼º Áúȯ¿¡ ´ëÇÑ Áø´Ü °Ë»ç¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» È®´ëÇÏ´Â µî STI ¿¹¹æ ¹× °ü¸® ÇÁ·Î±×·¥¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ³ë·Â°ú ÀÏ¹Ý ´ëÁßÀÇ ÀÎ½Ä °³¼± ¹× ±â¼ú ¹ßÀüÀÌ °áÇÕÇÏ¿© Ç츣Æä½º ¸¶Ä¿ °Ë»ç ½ÃÀåÀº ÇâÈÄ ¸î ³â µ¿¾È ²ÙÁØÈ÷ ¼ºÀåÇÏ¿© ´õ ¸¹Àº »ç¶÷µéÀÌ Á¤È®ÇÑ Áø´Ü°ú È¿°úÀûÀÎ Ä¡·á¸¦ ¹ÞÀ» ¼ö ÀÖ°Ô µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹½Ã(ÃÑ 13°Ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Herpes Marker Testing Market to Reach US$654.1 Million by 2030

The global market for Herpes Marker Testing estimated at US$468.1 Million in the year 2023, is expected to reach US$654.1 Million by 2030, growing at a CAGR of 4.9% over the analysis period 2023-2030. Diagnostic Centers End-Use, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach US$279.9 Million by the end of the analysis period. Growth in the Hospitals End-Use segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$124.1 Million While China is Forecast to Grow at 7.5% CAGR

The Herpes Marker Testing market in the U.S. is estimated at US$124.1 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$145.7 Million by the year 2030 trailing a CAGR of 7.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.4% and 4.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.8% CAGR.

Global Herpes Marker Testing Market - Key Trends and Drivers Summarized

Is Herpes Marker Testing the Key to Effective Management of Viral Infections?

Herpes marker testing plays a critical role in diagnosing and managing herpes simplex virus (HSV) infections, but why is this testing so essential? Herpes marker tests are used to detect the presence of antibodies or viral DNA in the body, helping clinicians identify whether an individual has been infected with HSV-1 or HSV-2, the two most common strains of the virus. HSV-1 is typically associated with oral herpes (cold sores), while HSV-2 is more commonly linked to genital herpes, although both types can infect either region. Herpes infections are widespread, with millions of people worldwide living with either type of the virus, many of whom are unaware they are carriers due to the often asymptomatic nature of the infection.

Herpes marker testing is critical for diagnosing the virus, particularly in asymptomatic individuals or those with mild symptoms, as they can unknowingly transmit the virus to others. Testing for herpes involves identifying specific antibodies (IgG or IgM) that the immune system produces in response to the infection or detecting viral DNA through polymerase chain reaction (PCR) tests. These tests help confirm whether someone has been exposed to the virus and, in many cases, can indicate whether the infection is recent or long-standing. Accurate diagnosis through herpes marker testing is essential for managing outbreaks, reducing the risk of transmission, and guiding treatment options to help individuals manage symptoms and prevent complications.

How Has Technology Advanced Herpes Marker Testing?

Technological advancements have significantly improved herpes marker testing, making it more accurate, faster, and accessible. One of the most significant innovations in this field is the development of polymerase chain reaction (PCR) testing, which allows for the direct detection of viral DNA. PCR testing is highly sensitive and can detect even small amounts of the virus in various sample types, such as blood, saliva, or lesion swabs. This method offers rapid and precise results, often within a few hours, making it one of the most reliable diagnostic tools for detecting active herpes infections. PCR tests have become the gold standard for diagnosing HSV infections, especially in cases where a definitive diagnosis is needed quickly, such as during an acute outbreak.

Serological testing, which identifies the presence of antibodies against HSV, has also improved. Traditional blood tests could sometimes struggle to differentiate between HSV-1 and HSV-2 infections. However, modern serological tests now offer type-specific antibody detection, allowing clinicians to distinguish between the two types of the virus. This distinction is crucial because HSV-1 and HSV-2 have different transmission patterns and recurrence rates, which can influence how a patient manages their infection. Type-specific IgG antibody tests can indicate whether someone has had a past infection, while IgM tests help identify recent or primary infections.

Additionally, point-of-care (POC) testing for herpes is becoming increasingly available. These rapid tests offer on-the-spot results, making them useful in urgent care or sexual health clinics where quick diagnosis is critical. Newer technologies are also exploring multiplex testing, which allows for the simultaneous detection of multiple sexually transmitted infections (STIs) alongside HSV, improving efficiency and reducing the number of tests needed to diagnose co-infections. These advancements in herpes marker testing not only improve diagnostic accuracy but also speed up the process, enabling earlier intervention and better management of herpes infections.

Why Is Herpes Marker Testing Critical for Public Health and Personal Management?

Herpes marker testing is vital for public health and personal management because it enables individuals and healthcare providers to detect and control the spread of herpes simplex virus infections, particularly when symptoms are mild or absent. Many people with herpes are unaware of their infection because it can remain dormant in the body for long periods, only causing outbreaks when triggered by factors like stress, illness, or a weakened immune system. Without proper testing, these individuals may unknowingly transmit the virus to others, contributing to its spread. Testing for herpes markers helps identify carriers and allows them to take precautions, such as using antiviral medications or practicing safer sexual behaviors, to reduce the risk of transmission.

For individuals, herpes marker testing provides clarity and peace of mind, particularly if they are experiencing unexplained symptoms like genital or oral sores, itching, or discomfort. A confirmed diagnosis allows healthcare providers to develop a tailored management plan, which may include antiviral medications like acyclovir, valacyclovir, or famciclovir to reduce the frequency and severity of outbreaks. Knowing their HSV status also empowers individuals to take preventive steps to avoid passing the virus to sexual partners, especially during asymptomatic shedding when the virus can still be transmitted.

In pregnant women, herpes marker testing is particularly critical. HSV infections, especially when acquired during pregnancy, can pose risks to the baby, leading to neonatal herpes, a serious condition that can cause permanent disability or death if not treated promptly. Identifying herpes infections early allows doctors to take preventive measures, such as prescribing antiviral medications in the late stages of pregnancy or recommending a cesarean delivery if there are active lesions during labor, to reduce the risk of transmitting the virus to the newborn.

On a larger scale, herpes marker testing is crucial for managing the overall public health impact of HSV infections. The virus is one of the most prevalent sexually transmitted infections globally, and widespread testing can help reduce its transmission rate by identifying and treating carriers. Early detection and effective management of herpes infections also help reduce the stigma associated with the virus, which can prevent individuals from seeking testing or treatment. By normalizing testing and offering easy access to diagnostics, public health systems can more effectively manage the spread of HSV, protect vulnerable populations, and improve the quality of life for those living with the virus.

What Factors Are Driving the Growth of the Herpes Marker Testing Market?

The growth of the herpes marker testing market is driven by several key factors, including rising awareness of sexually transmitted infections (STIs), advancements in testing technologies, and the increasing prevalence of herpes simplex virus infections globally. One of the primary drivers is the growing awareness of STIs and the importance of regular screening. Public health campaigns and educational programs are encouraging more people to get tested for herpes and other STIs, particularly as awareness increases about the asymptomatic nature of HSV infections. This shift in public health awareness is leading to higher demand for herpes marker testing in clinics, hospitals, and at-home testing kits.

Technological advancements in diagnostic testing are also contributing to the growth of the herpes marker testing market. The development of more accurate, faster, and cost-effective tests, such as PCR and multiplex testing, is making herpes diagnostics more accessible to healthcare providers and patients. These technologies allow for quicker turnaround times, which is especially important in managing acute outbreaks and preventing transmission. The introduction of point-of-care (POC) tests that deliver rapid results is another factor fueling market expansion, particularly in regions where healthcare infrastructure may be limited or where immediate results are necessary for treatment decisions.

The rising prevalence of herpes infections is another significant factor driving market growth. The World Health Organization (WHO) estimates that more than 3.7 billion people under the age of 50 have HSV-1, and over 490 million people aged 15–49 have HSV-2. As these infections remain widespread and incurable, the demand for effective diagnostic tools to manage and monitor herpes infections continues to grow. The increasing recognition of the health risks associated with undiagnosed or untreated herpes, such as complications during pregnancy and heightened risk of HIV transmission, is prompting more individuals to seek testing.

The growth of at-home testing options is another trend contributing to market expansion. With the rise of telemedicine and digital health platforms, at-home herpes testing kits are becoming more popular, providing a convenient, discreet, and accessible way for individuals to learn their HSV status. These kits allow users to collect a sample at home and send it to a laboratory for analysis, with results delivered confidentially via secure online platforms. The convenience and privacy offered by these services are encouraging more people, particularly younger and tech-savvy populations, to take charge of their sexual health and get tested.

Lastly, increasing healthcare initiatives and government programs aimed at reducing the prevalence of sexually transmitted infections are driving demand for herpes marker testing. Governments and global health organizations are investing in STI prevention and control programs, which include expanding access to diagnostic testing for herpes and other infections. These initiatives, combined with greater public awareness and technological advancements, are expected to drive steady growth in the herpes marker testing market in the coming years, ensuring that more individuals can access accurate diagnostics and effective care.

Select Competitors (Total 13 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â